Payment overview · 2025
General Payments
$5,011.61
152 reported records · 17 companies
Healthcare provider profile · identity verified
Therese Marie Lango, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · FLORENCE, AL · NPI 1235136821
Verified facts
What the public records show
CMS Open Payments records show Therese Marie Lango, MD received $5,011.61 in general payments during 2025 across 152 reported records.
Abbott Laboratories accounted for 72.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 678 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 678 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $3,630.04 | 72.4% | 75 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $445.01 | 8.9% | 36 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $196.91 | 3.9% | 5 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $113.85 | 2.3% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$111.15 | 2.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.31 | 1.5% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.37 | 1.4% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $72.21 | 1.4% | 7 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $50.30 | 1.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.74 | 1.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.94 | 1.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.67 | 0.8% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $35.73 | 0.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.40 | 0.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.14 | 0.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.95 | 0.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.89 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,738.95 | 142 |
| Travel and Lodging | $2,272.66 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $2,161.57 | 16 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $1,181.50 | 16 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $441.72 | 35 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $113.85 | 3 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $88.17 | 20 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.31 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $72.37 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $72.21 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $66.69 | 4 | 2025 |
Source payment records
|
|||||
| ACCENT Normalized: accent |
Device | Abbott Laboratories | $62.37 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $55.92 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $53.52 | 13 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $50.30 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.94 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.67 | 2 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $37.58 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $27.27 | 5 | 2025 |
Source payment records
|
|||||
| ALLURE QUADRA Normalized: allure quadra |
Device | Abbott Laboratories | $21.08 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| DURATA Normalized: durata |
Device | Abbott Laboratories | $4.71 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $3.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 678 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 150 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
87 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
678 | 190 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
150 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
678 | 190 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 678 | 190 |
| Metoprolol Tartrate | Metoprolol Tartrate | 544 | 218 |
| Atorvastatin Calcium | Atorvastatin Calcium | 524 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 181 |
| Clopidogrel | Clopidogrel Bisulfate | 357 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 315 | 120 |
| Nitroglycerin | Nitroglycerin | 273 | 186 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 112 |
| Furosemide | Furosemide | 243 | 91 |
| Losartan Potassium | Losartan Potassium | 228 | 101 |
| Terazosin Hcl | Terazosin Hcl | 225 | 74 |
| Carvedilol | Carvedilol | 223 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 74 |
| Potassium Chloride | Potassium Chloride | 206 | 80 |
| Ranolazine Er | Ranolazine | 185 | 71 |
| Lisinopril | Lisinopril | 183 | 66 |
| Entresto | Sacubitril/Valsartan | 150 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 49 |
| Spironolactone | Spironolactone | 125 | 47 |
| Warfarin Sodium | Warfarin Sodium | 123 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 118 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 43 |
| Ezetimibe | Ezetimibe | 107 | 45 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 93 | 33 |
| Repatha Sureclick | Evolocumab | 93 | 25 |
| Xarelto | Rivaroxaban | 91 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 89 | 44 |
| Brilinta | Ticagrelor | 87 | 22 |
| Torsemide | Torsemide | 85 | 35 |
| Valsartan | Valsartan | 83 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 31 |
| Sotalol | Sotalol Hcl | 79 | 22 |
| Simvastatin | Simvastatin | 70 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 28 |
| Enalapril Maleate | Enalapril Maleate | 67 | 20 |
| Flecainide Acetate | Flecainide Acetate | 64 | 20 |
| Fenofibrate | Fenofibrate | 59 | 24 |
| Prasugrel Hcl | Prasugrel Hcl | 56 | 22 |
| Diltiazem Hcl | Diltiazem Hcl | 55 | 19 |
| Omeprazole | Omeprazole | 54 | 24 |
| Farxiga | Dapagliflozin Propanediol | 53 | 13 |
| Nitroglycerin Patch | Nitroglycerin | 42 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 41 | 12 |
| Cilostazol | Cilostazol | 41 | 15 |
| Atenolol | Atenolol | 40 | 19 |
| Ramipril | Ramipril | 39 | 17 |
| Benazepril Hcl | Benazepril Hcl | 31 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Irbesartan | Irbesartan | 29 | 11 |
| Midodrine Hcl | Midodrine Hcl | 27 | 13 |
| Jantoven | Warfarin Sodium | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Famotidine | Famotidine | 23 | 11 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Opsumit | Macitentan | 16 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Ambrisentan | Ambrisentan | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Tracleer | Bosentan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,011.61 · 152 records | Abbott Laboratories | ACCENT, ALLURE QUADRA, AMVUTTRA, ASSURITY, AURORA EV-ICD MRI SURESCAN, AVEIR, CARDIOMEMS, DURATA, ELIQUIS, ENSITE PRECISION, ENTRESTO, FARXIGA, GALLANT, Kerendia, LEQVIO, LifeVest, MERLIN@HOME, MICRA, MYCARELINK, NURTEC ODT, OPSYNVI, REPATHA, ROTAPRO, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Tyvaso, UPTRAVI, VERQUVO, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error